HighVista Strategies’s Third Harmonic Bio THRD Stock Holding History

HighVista Strategies’s Portfolio THRD Stock Details THRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-91,780	Closed	-$395K	–	132
2022 Q4	$395K	Buy	+91,780	New	+$1.54M	0.23%	82

Other funds holding THRD

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighVista Strategies's THRD Position: Q1 2023 in Review

HighVista Strategies sold out of Third Harmonic Bio (THRD) in Q1 2023, closing a stake of 91,780 shares — an estimated $395K sold.

HighVista Strategies first reported a position in THRD in Q4 2022 and held it in 1 quarter. The position peaked at $395K in Q4 2022. 49 funds tracked by Wall St. Rank hold THRD as of Q1 2023.

HighVista Strategies reported no remaining Third Harmonic Bio position as of Q1 2023 after selling out during the quarter.
HighVista Strategies sold 91,780 Third Harmonic Bio shares in Q1 2023, an estimated $395K.
HighVista Strategies first reported a position in Third Harmonic Bio in Q4 2022 and held it in 1 quarter.
HighVista Strategies's Third Harmonic Bio position peaked at $395K in Q4 2022.
49 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q1 2023.

Based on HighVista Strategies's 13F filing for Q1 2023, filed 15 May 2023.